This study sought to assess the incidence of transplant coronary artery disease (CAD) in Chinese heart recipients.
METHODS

Patients and treatment.
From October 1987 to June 1998, we had performed 92 cases of heart transplantation at the National Taiwan University Hospital. Eight-eight patients underwent orthotopic heart transplantation. Since 1997, we have used bicaval anastomosis, instead of standard midatrial anastomosis, for orthotopic transplantation especially in patients with high pulmonary vascular resistance. There were four cases of heterotopic heart transplantation for donor/recipient size mismatch in two (11) , poor donor heart function in one and high pulmonary vascular resistance before transplantation in one patient. There were two cases of successful simultaneous heart and kidney transplantation. One case with Marfan syndrome had successful combined heart transplantation and resection of dissecting aortic aneurysm of ascending aorta and aortic arch. Three patients had mechanical bridge to heart transplantation successfully using the Thoratec ventricular assist device. Postoperatively, we used extracorporeal membrane oxygenation for acute allograft failure in eight patients. Three of eight patients were successfully weaned and discharged.
All patients received triple-drug immunosuppressive therapy according to our heart transplantation protocol. Since 1995, we have used rabbit antithymocyte globulins for induction therapy. Azathioprine (4 mg/kg) was given 1 h before the operation. Solumedrol (1,000 mg) was infused during release of the aortic cross clamp. Rabbit antithymocyte globulin 1.5 to 2.5 mg/kg/day was given after transplantation for 5 days. Cyclosporine was started orally within 5 days after transplantation or after the recovery of renal function. Cyclosporine dose was adjusted according to renal function and serum cyclosporine level, which was maintained at the trough level of 300 to 500 ng/ml during the first 3 months after transplantation and 200 to 300 ng/ml 1 year after transplantation. Azathioprine was given at 1 to 2 mg/kg/day after transplantation, with the dose adjusted to maintain a white blood cell count 4,000 to 6,000/mm 3 . Prednisone (0.5 mg/kg/day) was started on the second postoperative day and tapered to 0.2 mg/kg/day by the 1st month after transplantation. Endomyocardial biopsy was performed weekly in the first month, biweekly in the second month, monthly in the sixth month and yearly six months after transplantation. Tacrolimus (FK-506) and mycophenolate mofetil (Cellcept) were used for recurrent rejection or severe adverse reactions to cyclosporine and azathioprine.
All patients discharged received 100 mg aspirin daily and 25 mg dipyridamole three times per day for prevention of transplant CAD. Hyperlipidemia was treated with dietary modification and body weight control first. Hypertriglyceridemia was treated with bezafibrate. Hypercholesterolemia was treated with pravastatin and acipimox. Hyperuricemia was treated with probenecid and allopurinol. Hyperglycemia was treated with oral hypoglycemic agent and insulin. Hypertension was treated with angiotensin-converting enzyme inhibitors and calcium antagonists. All patients were followed at a special cardiac transplant clinic. Data collection. For those patients surviving for more than six months after transplantation, coronary angiography and endomyocardial biopsy were performed annually for surveillance of transplant CAD. The coronary angiogram performed 1 month after transplantation was used for baseline data. Cineangiograms were recorded at 60 frames/s through a lens with a focal length of 135 mm and with an X-ray field of 15 cm. Multiple pairs of perpendicular views of the left and right coronary arteries were taken. All coronary angiograms were reviewed by two cardiologists in a blinded fashion. Coronary lesions were evaluated by on-line digital quantitative coronary angiograms (DCI System, Philips, Best, The Netherlands) (12) . The intraobserver and interobserver variations were 5% and 8%, respectively. The diagnosis of transplant CAD was made from the evidence of any coronary artery irregularity or diffuse narrowing in proximal and distal vessels. Transplant CAD was classified as localized atherosclerotic lesions or diffuse concentric narrowing. Endomyocardial biopsy was examined for ischemic myocardial pathology. Cardiac events including myocardial infarction, left ventricular dysfunction, arrhythmia and sudden death were recorded. The recipient characteristics (age, gender, body weight, smoking, hypertension, diabetes, cholesterol level, triglyceride level and viral infection), donor characteristics (age, gender, preexisting coronary artery disease and allograft ischemic time), rejection episodes, medications and human leukocyte antigen (HLA) match were recorded. Cytomegalovirus (CMV) infection was defined as a fourfold rise in antibody, CMV inclusion body or positive culture. Rejection was defined as biopsyproven pathologic finding and clinical event leading to specific immunosuppressive intervention.
Statistical analysis.
Comparisons between groups were determined by the two-tailed t test for difference in proportion and means. A difference of p Ͻ 0.05 was considered statistically significant.
RESULTS
Among these 92 heart transplant recipients, seven patients died within the first month after transplantation because of bleeding in 3, acute rejection in 2, arrhythmia in 1 and cerebral injury in 1 patient. Another 10 patients died within the first year after transplantation because of infection in 5, rejection in 3 (two for medical noncompliance) and arrhythmia and gastrointestinal bleeding each in one patient. The operative mortality rate was 7.6%. The one-year survival rate was 81.5%. Twenty-five of 92 cardiac transplant patients are alive less than 1 year after transplantation and could not be evaluated for this study. At the time of this study, obesity was present in 17, hypertension in 21, hyperuricemia in 27, diabetes in 17, renal dysfunction in 21 and hyperlipidemia in 34 of 50 patients. No patients used diltiazem. Pravastatin was used in 12 patients for hyperlipidemia.
Fifty patients survived for more than one year and were included in this study. Among these 50 patients, there were 42 men and 8 women. The clinical diagnosis of end-stage heart failure was idiopathic dilated cardiomyopathy in 31 (62%), ischemic heart disease in 13 (26%), valvular heart disease in 4 (8%), congenital heart disease and postpartum cardiomyopathy in 1 patient. The mean recipient age was 44.1 Ϯ 13.6 years at the time of transplantation. The mean donor age was 29.4 Ϯ 10.8 years (range 15 to 55). Positive CMV antibody was present in 44 of 48 recipients (91.7%) and 27 of 30 donors (90%) at the time of transplantation. The allograft ischemic time was 45 to 223 min (mean 101.1).
Rejection. Thirty-two patients had a biopsy-proven episode of acute rejection within the 1st year after transplantation, with an incidence of rejection of 64% within 1 year after transplantation. The mean number of rejection episodes in the 1st year after transplantation was 1.15. Among the ninety-two cases of heart transplantation, two patients had acute vascular rejection and died in spite of mechanical circulatory support, plasmapheresis and immunoadsorption therapy. Rejection rarely occurred in patients more than one year after transplantation. Only two recipients had late acute rejection.
Infection. During the follow-up period, eight patients had major infection. Among these 50 recipients, seven patients (14%) were hepatitis B carriers. Three of seven carriers had liver failure due to hepatitis B reactivation. Two patients were treated successfully with lamivudine. One patient had liver cirrhosis at eight years after transplantation. Two patients (4%) had active CMV infection and were treated with ganciclovir therapy. One patient had Aspergillus infection and was cured by amphotericin infusion and wedge resection of infected lung (13) . There was one patient with malignant lymphoma of small intestine. No patient had solid organ tumor or Kaposi sarcoma after transplantation.
Cardiac event. Cardiac events occurred in three patients. One patient had atrial arrhythmia. One patient had biopsynegative left ventricular dysfunction and the coronary angiogram was patent. Another patient with heterotopic heart transplantation had sudden arrest of donor heart. The coronary artery was patent and the pathology was massive coagulation necrosis. The patient was doing well for improved native heart function due to prolonged unloading of native heart after heterotopic heart transplantation.
Human leukocyte antigen mismatch. Complete HLA information on the A, B and DR loci was available for both donor and recipient in 47 patients. Seven patients (14.9%) had two or fewer HLA mismatches, whereas three patients (6.4%) had mismatches of all six HLA loci (Table 1) .
Transplant CAD. Coronary angiography was reviewed by at least two cardiologists at the time of study. Among 74 angiograms of 50 patients reviewed, only one patient had discrete stenosis less than 50% in the middle part of the left anterior descending artery at one year after transplantation. This patient, a 39-year old man, was a case of ischemic heart disease and received heart transplantation for end-stage heart failure. He had two rejection episodes in the first year after transplantation. No coronary angioplasty was performed then, because he was free of angina and left ventricular dysfunction. No patient had diffuse narrowing of coronary artery. The cumulative incidence of transplant CAD was 2% (1/50) at 1 year and 2% at 2 years (30 cases) and 4 years (10 cases) after transplantation. In all specimens of endomyocardial biopsy after 1 year posttransplant, there was no evidence of ischemic myocardial pathology including subendocardial myocyte vacuolization and coagulative myocyte necrosis as described by Winters and Schoen (14) .
DISCUSSION
Transplant CAD. Heart transplantation has become a highly effective therapy for patients with end-stage heart diseases. With advances in management of infectious complications and immunosuppressive therapy, the survival after heart transplantation continues to improve. In the 1993 Registry of the International Society for Heart and Lung Transplantation, the one-year and five-year survival rates after heart transplantation were 79.1% and 67.8% (15) . Although modern immunosuppressive therapy has reduced death caused by acute rejection and infection, late mortality as a result of transplant CAD remains an unresolved problem (3) (4) (5) (6) (7) (8) . In a multi-institutional study (9) , the prevalence of transplant CAD detected by angiography was 11%, 22% and 45% at 1, 2 and 4 years after transplantation, respectively. Transplant CAD is an accelerated form of atherosclerosis, characterized by rapid development of intimal hyperplasia and smooth muscle cell proliferation (16) . It accounts for 36% of deaths in patients who survive 1 year after transplantation and for 60% of retransplantation (17, 18) . Myocardial revascularization procedures, including coronary angioplasty (19) , coronary artery bypass (20) and transmyocardial laser revascularization (21) , have limited role in the management of transplant CAD for diffuse narrowing of distal coronary artery. Retransplantation is also associated with higher mortality and morbidity (18) . It is imperative to understand the risk factors and pathogenesis of transplant CAD and to prevent its development and progression.
Heart transplantation in Asia. Asia has more than 50% of the world's population, but the number of heart transplantation up to December 1996 was only 380 cases. This number is quite small in contrast to the huge number performed in America and Europe. The major problem has been that the acceptance of the concept of brain death as the definition of death of the patient is difficult for Oriental people due to cultural and religious reasons. Most Chinese people want to keep the whole body buried after death. Although Taiwan is a small island with a population of 22 million, about half the number of heart transplantations in Asia have been performed in Taiwan. This provided us a chance to evaluate the incidence of transplant CAD in Chinese heart recipients. In this study, the incidence of transplant CAD in our patients was only 2% at 1 year and none at 2 and 4 years after transplantation. This was much lower compared with the Western series (3,9). 
Risk factors. Numerous studies have investigated the possible risk factors for the development of transplant CAD (3) (4) (5) (6) (7) (8) . Controversies still exist regarding donor and recipient factors which promote the development and progression of CAD after transplantation. Both immunologic and nonimmunologic factors could contribute to the occurrence of transplant coronary artery disease. Older recipient age, older donor age, male recipient, female donor, recipient with ischemic heart disease, allograft ischemic time, CMV infection, hyperlipidemia, obesity, immunosuppression, acute rejection, prophylactic diltiazem use, HLA mismatches and racial disparity have been recognized as the risk factors (3) (4) (5) (6) (7) (8) (9) (22) (23) (24) (25) . In Table 2 , we compare the donor and recipient characteristics between our patients and Western patients (3) (4) (5) (6) (7) (8) 24) . The donor age, recipient age and percentage of male gender were the same. Pretransplant diagnosis of recipients in our study was less due to ischemic heart disease. The prevalence of ischemic heart disease is low in Oriental countries possibly due to low fat and high vegetable diet.
Cytomegalovirus infection.
Human CMV infection has been recognized as a significant risk factor of transplant CAD, and prophylactic ganciclovir therapy may protect against the development of transplant CAD (3, 22) . In this study, more than 90% of donors and recipients had positive CMV antibody before transplantation. The incidence of CMV mismatches between donors and recipients was also low. The percentage of CMV seronegative recipients was only 8.3% in this study. Thus the chance of primary CMV infection after transplantation was reduced. In fact, people in Taiwan usually had CMV infection by airborne transmission before adulthood. This accounts for the high incidence of past CMV infection before transplantation.
Human leukocyte antigen mismatch. Previous studies have shown that HLA mismatches are associated with a higher incidence and severity of transplant CAD (3, 23) . The pathogenic mechanism of transplant CAD is thought to be primarily immune-mediated. Both cellular and humoral immunities are involved. Besides, race and donor/ recipient race mismatch may influence the development of transplant CAD. African-Americans have increased early mortality due to transplant CAD (24) . In this study, the donors and recipients were all Chinese except one white donor from Ireland. Thus the race mismatch was only one of 50 recipients. The HLA mismatch was also low in this study. The incidence of HLA mismatches two or less in A, B and DR loci was 14.9%, compared with 6% in Western series (26) .
Rejection. Previous studies have shown that the risk of transplant CAD may be increased by acute graft rejection (6, 25) . In this study, we used antithymocyte globulin for induction and higher doses of cyclosporine for maintenance immunosuppression. The incidence of rejection within one year after transplantation was the same between this study and Western series (26) . But the mean number of rejection 
